Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Portfolio Pulse from
Medicenna presented preclinical data on MDNA11, showing its effectiveness in shrinking tumors and preventing metastasis in a mouse model of triple negative breast cancer. MDNA11 outperformed a combination of immune checkpoint inhibitors.
December 13, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medicenna's MDNA11 demonstrated superior efficacy in preclinical trials for TNBC, outperforming immune checkpoint inhibitors in tumor shrinkage and metastasis prevention.
The preclinical success of MDNA11 in a challenging cancer model suggests potential for future clinical success, which could positively impact Medicenna's stock price. The data presented at a major symposium adds credibility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100